Skip to main content
. 2012 Jul 16;103(9):1708–1713. doi: 10.1111/j.1349-7006.2012.02354.x

Table 3.

Subgroup analysis for response to TAS‐108 within each dose group (tumor refractory to prior tamoxifen and aromatase inhibitor treatment)

Tamoxifen refractory (n = 14) Aromatase inhibitor refractory (n = 70)
Clinical benefit rate (%) 28.6 27.1